PE20040613A1 - Estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva - Google Patents

Estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva

Info

Publication number
PE20040613A1
PE20040613A1 PE2003000575A PE2003000575A PE20040613A1 PE 20040613 A1 PE20040613 A1 PE 20040613A1 PE 2003000575 A PE2003000575 A PE 2003000575A PE 2003000575 A PE2003000575 A PE 2003000575A PE 20040613 A1 PE20040613 A1 PE 20040613A1
Authority
PE
Peru
Prior art keywords
estra
stratriens
estrogens
alpha
substituted
Prior art date
Application number
PE2003000575A
Other languages
English (en)
Spanish (es)
Inventor
Gerd Muller
Dirk Kosemund
Peter Muhn
Alexander Hillisch
Karl-Heinrich Fritzemeier
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20040613A1 publication Critical patent/PE20040613A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2003000575A 2002-06-11 2003-06-10 Estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva PE20040613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10226326A DE10226326A1 (de) 2002-06-11 2002-06-11 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene

Publications (1)

Publication Number Publication Date
PE20040613A1 true PE20040613A1 (es) 2004-12-01

Family

ID=29723144

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000575A PE20040613A1 (es) 2002-06-11 2003-06-10 Estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva

Country Status (28)

Country Link
EP (1) EP1517914B1 (enExample)
JP (1) JP4615998B2 (enExample)
KR (1) KR101006612B1 (enExample)
CN (1) CN1293090C (enExample)
AR (1) AR040188A1 (enExample)
AT (1) ATE303397T1 (enExample)
AU (1) AU2003242683B9 (enExample)
BR (1) BR0312140A (enExample)
CA (1) CA2486495C (enExample)
CR (1) CR10289A (enExample)
CU (1) CU23414B7 (enExample)
DE (2) DE10226326A1 (enExample)
DK (1) DK1517914T3 (enExample)
EA (1) EA008442B1 (enExample)
EC (1) ECSP055530A (enExample)
ES (1) ES2248770T3 (enExample)
HR (1) HRP20050009B1 (enExample)
IL (1) IL165321A (enExample)
MX (1) MXPA04012491A (enExample)
NO (1) NO329563B1 (enExample)
PE (1) PE20040613A1 (enExample)
PL (1) PL209910B1 (enExample)
RS (1) RS50878B (enExample)
TW (1) TWI286140B (enExample)
UA (1) UA78062C2 (enExample)
UY (1) UY27844A1 (enExample)
WO (1) WO2003104253A2 (enExample)
ZA (1) ZA200500217B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP1689410B1 (en) * 2003-11-26 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP2252261A2 (en) * 2008-02-13 2010-11-24 Bayer Schering Pharma Aktiengesellschaft Drug delivery system with stabilising effect
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
WO2010057594A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
EP3185881B1 (en) 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
CA3109978A1 (en) * 2018-09-07 2020-03-12 Trustees Of Dartmouth College C19 scaffolds and steroids and methods of use and manufacture thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336432A1 (de) * 1973-07-13 1975-01-30 Schering Ag 3.17.18-trihydroxy-1.3.5(10)-oestratriene
US6154158A (en) * 1998-06-30 2000-11-28 Qualcomm Incorporated Digital-to-analog converter D.C. offset correction comparing converter input and output signals
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene
EP1226155B1 (de) * 1999-11-02 2007-05-02 Bayer Schering Pharma AG 18-nor-steroide als selektiv wirksame estrogene
AU5834101A (en) * 2000-04-12 2001-10-23 Schering Ag 8ss-hydrocarbyl-substituted estratrienes for use as selective estrogens

Also Published As

Publication number Publication date
CA2486495C (en) 2011-04-19
TWI286140B (en) 2007-09-01
PL373090A1 (en) 2005-08-08
HRP20050009B1 (hr) 2013-07-31
ES2248770T3 (es) 2006-03-16
AU2003242683A1 (en) 2003-12-22
NO20050127L (no) 2005-03-11
WO2003104253A2 (de) 2003-12-18
ZA200500217B (en) 2006-03-29
DE10226326A1 (de) 2004-01-15
CN1659181A (zh) 2005-08-24
JP4615998B2 (ja) 2011-01-19
CN1293090C (zh) 2007-01-03
KR20050009745A (ko) 2005-01-25
DK1517914T3 (da) 2006-01-16
AU2003242683B2 (en) 2009-07-02
NO20050127D0 (no) 2005-01-10
NO329563B1 (no) 2010-11-15
ECSP055530A (es) 2005-03-10
HRP20050009A2 (en) 2005-04-30
KR101006612B1 (ko) 2011-01-10
HK1081203A1 (en) 2006-05-12
PL209910B1 (pl) 2011-11-30
TW200407331A (en) 2004-05-16
UA78062C2 (en) 2007-02-15
IL165321A (en) 2009-08-03
CR10289A (es) 2008-11-26
EP1517914A2 (de) 2005-03-30
CU23414B7 (es) 2009-09-08
UY27844A1 (es) 2003-12-31
CA2486495A1 (en) 2003-12-18
DE50301116D1 (de) 2005-10-06
MXPA04012491A (es) 2005-06-08
RS50878B (sr) 2010-08-31
RS107004A (sr) 2006-10-27
EA008442B1 (ru) 2007-06-29
AU2003242683B9 (en) 2009-08-27
AR040188A1 (es) 2005-03-16
JP2005533053A (ja) 2005-11-04
EP1517914B1 (de) 2005-08-31
BR0312140A (pt) 2005-04-05
WO2003104253A3 (de) 2004-09-16
EA200401544A1 (ru) 2005-06-30
ATE303397T1 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
AP2002002561A0 (en) 5-HT receptor ligards and uses thereof.
PE20040613A1 (es) Estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva
PE20040165A1 (es) Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular
ES2177112T3 (es) Agentes angiostaticos y composiciones para tratar el glaucoma glc1a.
DE60022042D1 (de) Thieno- und furopyrimidin derivate als a2a-rezeptor antagonisten
DE60303381D1 (de) Neue indolylpiperidin-derivate als potente antihistaminische und antiallergische mittel
ATE266636T1 (de) Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren
ATE337730T1 (de) Vorrichtung zum behandeln der weiblichen harninkontinenz
DE60335911D1 (de) Isochinolinonderivate und deren verwendung als medikamente
ATE478670T1 (de) Rezeptor-selektive cannabimimetische aminoalkylindole
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
UY28150A1 (es) Agentes terapeuticos
MY129445A (en) Compositions for treating inflammatory response
CO5271666A1 (es) Derivados de pirimidina
CY1106409T1 (el) Παραγωγα κινολινης
BR0307903A (pt) derivados de arilsulfona
CY1105607T1 (el) Η χρηση ενος η1 ανταγωνιστη και ριμεξαολης ως ενα ασφαλες στεροειδες για την θεραπεια ρινιτιδας
DE60013486D1 (de) Verbindungen
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
SG147469A1 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
PT1497292E (pt) Derivados de azaindolilpiperidina como agentes anti-histaminicos e antialergicos
DE69819742D1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
BR0315140A (pt) Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação
PE20020472A1 (es) Uso de un inhibidor del receptor de progesterona para inhibir la fijacion de factores de crecimiento en celulas tumorales
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.

Legal Events

Date Code Title Description
FC Refusal